Format

Send to

Choose Destination
Curr Mol Med. 2012 Jan;12(1):96-110.

Basal breast cancer: a complex and deadly molecular subtype.

Author information

1
Département d'Oncologie Médicale, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, UMR891 Inserm, Marseille, France. bertuccif@marseille.fnclcc.fr

Abstract

During the last decade, gene expression profiling of breast cancer has revealed the existence of five molecular subtypes and allowed the establishment of a new classification. The basal subtype, which represents 15-25% of cases, is characterized by an expression profile similar to that of myoepithelial normal mammary cells. Basal tumors are frequently assimilated to triple-negative (TN) breast cancers. They display epidemiological and clinico-pathological features distinct from other subtypes. Their pattern of relapse is characterized by frequent and early relapses and visceral locations. Despite a relative sensitivity to chemotherapy, the prognosis is poor. Recent characterization of their molecular features, such as the dysfunction of the BRCA1 pathway or the frequent expression of EGFR, provides opportunities for optimizing the systemic treatment. Several clinical trials dedicated to basal or TN tumors are testing cytotoxic agents and/or molecularly targeted therapies. This review summarizes the current state of knowledge of this aggressive and hard-to-treat subtype of breast cancer.

PMID:
22082486
PMCID:
PMC3343384
DOI:
10.2174/156652412798376134
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd. Icon for PubMed Central
Loading ...
Support Center